Matthieu Gras
Research Subjects
Matthieu Gras has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Rodrigue Garcia
Cardiology Department & Centre d'Investigation Clinique 1402, University Hospital Centre Poitiers, Poitiers, France
4 shared publications - Bruno Degand
Department of Cardiology, CHU de Poitiers , Poitiers
3 shared publications - Anthony Li
City St George’s, University of London, United Kingdom (M.C.W., A.C.L., M.M.S.).
2 shared publications - Benjamin Alos
Cardiology Department, CHU Poitiers , 2, Rue de la Milétrie, Poitiers F-86021
2 shared publications - Charles Guenancia
Department of Cardiology, Université Bourgogne Europe, CHU Dijon Bourgogne, EA7460 PEC2 , 14 rue Paul Gaffarel, Dijon 21000
2 shared publications - Claire Bouleti
Cardiology Department, University Hospital of Poitiers, Clinical Investigation Center (Inserm 1402), Poitiers, France
2 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (10)
Elimination of epicardial late potentials by endocardial ablation in arrhythmogenic right ventricular cardiomyopathy
- 28 August 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (10)
Open AccessElimination of epicardial late potentials by endocardial ablation in arrhythmogenic right ventricular cardiomyopathy
- Open Access
- 13 November 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 7 (2)
Impact and safety of remote monitoring of heart failure patients managed with the HeartLogic algorithm: the HeartLogic France Cohort Study
Aims: HeartLogic, an algorithm in implanted devices, predicts heart failure (HF) episodes via a remotely monitored index, aiding proactive congestion treatment to prevent acute decompensation. This study assessed the efficacy and safety of pre-emptive HF management using the HeartLogic index. Methods and results: The HeartLogic France Cohort Study is a prospective multicentre investigation involving 310 HF patients with implanted cardioverter defibrillators enrolled from 10 French centres. The HeartLogic™ index was monitored for 12 months, and when the index reached ≥16, patients were contacted to adjust HF treatment. The primary endpoint was unscheduled hospitalization for HF. An independent blinded committee adjudicated the events. A total of 309 patients (65 ± 10 years old; 83.5% male, left ventricular ejection fraction 31 ± 9%) were included in the analysis. Ischemic cardiomyopathy was present in 61.2% (n = 189) of the patients, and 52.8% (n = 163) had a cardiac resynchronization therapy device. During follow-up, 406 alerts occurred in 158 patients (1.33 alerts/patient-year), resulting in treatment modification in 39.6% of alerts. A total of 24 unplanned HF hospitalizations occurred in 19 (6.1%) patients. Sixteen (66.7%) of those hospitalizations were preceded by a HeartLogic alert, of which 14 (87.5%) triggered a drug modification before hospitalization. Eighteen deaths (5.8%) occurred, including 10 due to cardiovascular causes. An increase in creatinine ≥30% and symptomatic hypotension were reported in two patients. Hyperkalemia and hyponatremia were not observed. Conclusion: Pre-emptive HF management guided by the HeartLogic index was associated with low rates of unplanned hospitalizations and adverse events over a 12-month follow-up period. Study registration: ClinicalTrials.gov, ID: NCT04619888.
- 13 November 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 7 (2)
Open AccessImpact and safety of remote monitoring of heart failure patients managed with the HeartLogic algorithm: the HeartLogic France Cohort Study
Aims: HeartLogic, an algorithm in implanted devices, predicts heart failure (HF) episodes via a remotely monitored index, aiding proactive congestion treatment to prevent acute decompensation. This study assessed the efficacy and safety of pre-emptive HF management using the HeartLogic index. Methods and results: The HeartLogic France Cohort Study is a prospective multicentre investigation involving 310 HF patients with implanted cardioverter defibrillators enrolled from 10 French centres. The HeartLogic™ index was monitored for 12 months, and when the index reached ≥16, patients were contacted to adjust HF treatment. The primary endpoint was unscheduled hospitalization for HF. An independent blinded committee adjudicated the events. A total of 309 patients (65 ± 10 years old; 83.5% male, left ventricular ejection fraction 31 ± 9%) were included in the analysis. Ischemic cardiomyopathy was present in 61.2% (n = 189) of the patients, and 52.8% (n = 163) had a cardiac resynchronization therapy device. During follow-up, 406 alerts occurred in 158 patients (1.33 alerts/patient-year), resulting in treatment modification in 39.6% of alerts. A total of 24 unplanned HF hospitalizations occurred in 19 (6.1%) patients. Sixteen (66.7%) of those hospitalizations were preceded by a HeartLogic alert, of which 14 (87.5%) triggered a drug modification before hospitalization. Eighteen deaths (5.8%) occurred, including 10 due to cardiovascular causes. An increase in creatinine ≥30% and symptomatic hypotension were reported in two patients. Hyperkalemia and hyponatremia were not observed. Conclusion: Pre-emptive HF management guided by the HeartLogic index was associated with low rates of unplanned hospitalizations and adverse events over a 12-month follow-up period. Study registration: ClinicalTrials.gov, ID: NCT04619888.
- 26 September 2021
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 44 (11) , 1853-1860
Independent factors of low radiation dose during atrial fibrillation ablation with cryoballoon or radiofrequency: Results from the “Go for zero fluoroscopy” registry
Click on the article title to read more.
- 26 September 2021
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 44 (11) , 1853-1860
Independent factors of low radiation dose during atrial fibrillation ablation with cryoballoon or radiofrequency: Results from the “Go for zero fluoroscopy” registry
Click on the article title to read more.
- Open Access
- 27 May 2021
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 23 (5) , e26349
Virtual Reality for Sedation During Atrial Fibrillation Ablation in Clinical Practice: Observational Study
Background: Connected devices are dramatically changing many aspects in health care. One such device, the virtual reality (VR) headset, has recently been shown to improve analgesia in a small sample of patients undergoing transcatheter aortic valve implantation. Objective: We aimed to investigate the feasibility and effectiveness of VR in patients undergoing atrial fibrillation (AF) ablation under conscious sedation. Methods: All patients who underwent an AF ablation with VR from March to May 2020 were included. Patients were compared to a consecutive cohort of patients who underwent AF ablation in the 3 months prior to the study. Primary efficacy was assessed by using a visual analog scale, summarizing the overall pain experienced during the ablation. Results: The AF cryoablation procedure with VR was performed for 48 patients (mean age 63.0, SD 10.9 years; n=16, 33.3% females). No patient refused to use the device, although 14.6% (n=7) terminated the VR session prematurely. Preparation of the VR headset took on average 78 (SD 13) seconds. Compared to the control group, the mean perceived pain, assessed with the visual analog scale, was lower in the VR group (3.5 [SD 1.5] vs 4.3 [SD 1.6]; P=.004), and comfort was higher in the VR group (7.5 [SD 1.6] vs 6.8 [SD 1.7]; P=.03). On the other hand, morphine consumption was not different between the groups. Lastly, complications, as well as procedure and fluoroscopy duration, were not different between the two groups. Conclusions: We found that VR was associated with a reduction in the perception of pain in patients undergoing AF ablation under conscious sedation. Our findings demonstrate that VR can be easily incorporated into the standard ablation workflow.
- 27 May 2021
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 23 (5) , e26349
Open AccessVirtual Reality for Sedation During Atrial Fibrillation Ablation in Clinical Practice: Observational Study
Background: Connected devices are dramatically changing many aspects in health care. One such device, the virtual reality (VR) headset, has recently been shown to improve analgesia in a small sample of patients undergoing transcatheter aortic valve implantation. Objective: We aimed to investigate the feasibility and effectiveness of VR in patients undergoing atrial fibrillation (AF) ablation under conscious sedation. Methods: All patients who underwent an AF ablation with VR from March to May 2020 were included. Patients were compared to a consecutive cohort of patients who underwent AF ablation in the 3 months prior to the study. Primary efficacy was assessed by using a visual analog scale, summarizing the overall pain experienced during the ablation. Results: The AF cryoablation procedure with VR was performed for 48 patients (mean age 63.0, SD 10.9 years; n=16, 33.3% females). No patient refused to use the device, although 14.6% (n=7) terminated the VR session prematurely. Preparation of the VR headset took on average 78 (SD 13) seconds. Compared to the control group, the mean perceived pain, assessed with the visual analog scale, was lower in the VR group (3.5 [SD 1.5] vs 4.3 [SD 1.6]; P=.004), and comfort was higher in the VR group (7.5 [SD 1.6] vs 6.8 [SD 1.7]; P=.03). On the other hand, morphine consumption was not different between the groups. Lastly, complications, as well as procedure and fluoroscopy duration, were not different between the two groups. Conclusions: We found that VR was associated with a reduction in the perception of pain in patients undergoing AF ablation under conscious sedation. Our findings demonstrate that VR can be easily incorporated into the standard ablation workflow.
- Open Access
- 8 December 2020
- Published by JMIR Publications Inc. in JMIR Preprints
Virtual Reality for Sedation During Atrial Fibrillation Ablation in Clinical Practice: Observational Study (Preprint)
BACKGROUND Connected devices are dramatically changing many aspects in health care. One such device, the virtual reality (VR) headset, has recently been shown to improve analgesia in a small sample of patients undergoing transcatheter aortic valve implantation. OBJECTIVE We aimed to investigate the feasibility and effectiveness of VR in patients undergoing atrial fibrillation (AF) ablation under conscious sedation. METHODS All patients who underwent an AF ablation with VR from March to May 2020 were included. Patients were compared to a consecutive cohort of patients who underwent AF ablation in the 3 months prior to the study. Primary efficacy was assessed by using a visual analog scale, summarizing the overall pain experienced during the ablation. RESULTS The AF cryoablation procedure with VR was performed for 48 patients (mean age 63.0, SD 10.9 years; n=16, 33.3% females). No patient refused to use the device, although 14.6% (n=7) terminated the VR session prematurely. Preparation of the VR headset took on average 78 (SD 13) seconds. Compared to the control group, the mean perceived pain, assessed with the visual analog scale, was lower in the VR group (3.5 [SD 1.5] vs 4.3 [SD 1.6]; P=.004), and comfort was higher in the VR group (7.5 [SD 1.6] vs 6.8 [SD 1.7]; P=.03). On the other hand, morphine consumption was not different between the groups. Lastly, complications, as well as procedure and fluoroscopy duration, were not different between the two groups. CONCLUSIONS We found that VR was associated with a reduction in the perception of pain in patients undergoing AF ablation under conscious sedation. Our findings demonstrate that VR can be easily incorporated into the standard ablation workflow.
- 8 December 2020
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessVirtual Reality for Sedation During Atrial Fibrillation Ablation in Clinical Practice: Observational Study (Preprint)
BACKGROUND Connected devices are dramatically changing many aspects in health care. One such device, the virtual reality (VR) headset, has recently been shown to improve analgesia in a small sample of patients undergoing transcatheter aortic valve implantation. OBJECTIVE We aimed to investigate the feasibility and effectiveness of VR in patients undergoing atrial fibrillation (AF) ablation under conscious sedation. METHODS All patients who underwent an AF ablation with VR from March to May 2020 were included. Patients were compared to a consecutive cohort of patients who underwent AF ablation in the 3 months prior to the study. Primary efficacy was assessed by using a visual analog scale, summarizing the overall pain experienced during the ablation. RESULTS The AF cryoablation procedure with VR was performed for 48 patients (mean age 63.0, SD 10.9 years; n=16, 33.3% females). No patient refused to use the device, although 14.6% (n=7) terminated the VR session prematurely. Preparation of the VR headset took on average 78 (SD 13) seconds. Compared to the control group, the mean perceived pain, assessed with the visual analog scale, was lower in the VR group (3.5 [SD 1.5] vs 4.3 [SD 1.6]; P=.004), and comfort was higher in the VR group (7.5 [SD 1.6] vs 6.8 [SD 1.7]; P=.03). On the other hand, morphine consumption was not different between the groups. Lastly, complications, as well as procedure and fluoroscopy duration, were not different between the two groups. CONCLUSIONS We found that VR was associated with a reduction in the perception of pain in patients undergoing AF ablation under conscious sedation. Our findings demonstrate that VR can be easily incorporated into the standard ablation workflow.